Michael A Nauck (Michael Nauck, Juris J Meier, M A Nauck)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 52

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Journal of diabetes science and technology

Nature reviews. Endocrinology

Katholisches Klinikum Bochum Sankt Josef-Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Katholisches Klinikum Bochum Sankt Josef-Hospital Jan 01 2015

Germany

Head, Clinical Research Diabetes :: Diabetes Division

Publications

Thomas Karagiannis, Apostolos Tsapas, Apostolos Tsapas, Konstantinos A Toulis, Michael A Nauck
A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes. Diabetes care 47 (2) (2024)
Daniel Robert Quast, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Karen Louise Jones, Michael Horowitz, Juris J Meier, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Daniel Robert Quast, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Karen Louise Jones, Michael Horowitz, Juris J Meier, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, obesity & metabolism 26 (9) (2024)
Karen Louise Jones, Christopher K Rayner, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck, Michael Horowitz
Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure. Diabetes, obesity & metabolism 26 (8) (2024)
Thomas Karagiannis, Apostolos Tsapas, Apostolos Tsapas, Konstantinos A Toulis, Michael A Nauck
A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes. Diabetes care 47 (2) (2024)
Karen Louise Jones, Christopher K Rayner, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck, Michael Horowitz
Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure. Diabetes, obesity & metabolism (2024)
Thomas Karagiannis, Apostolos Tsapas, Apostolos Tsapas, Konstantinos A Toulis, Michael A Nauck
A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes. Diabetes care 47 (2) (2024)
Ruben Nogueiras, Michael A Nauck, Matthias H Tschöp
Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nature metabolism (2023)
Michael A Nauck, Abd El Aziz Mirna, Daniel R Quast
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Diabetes, obesity & metabolism (2023)
Ryan Joseph Jalleh, Karen Louise Jones, Michael A Nauck, Michael Horowitz
Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists. Annals of internal medicine (2023)
Michael A Nauck, Mirna Abd El Aziz, Daniel R Quast
Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin - An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide. Diabetes, obesity & metabolism (2023)
Dominik Wollenhaupt, Jannik Wolters, Mirna Abd El Aziz, Michael A Nauck
Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis. BMJ open diabetes research & care 11 (4) (2023)
Juris J Meier, Daniel Robert Quast, Michael A Nauck, Nina Schenker, Carolyn F Deacon, Jens J Holst, Leona Plum-Mörschel, Christoph Kapitza
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, obesity & metabolism 24 (5) (2022)
Jannik Wolters, Dominik Wollenhaupt, Mirna Abd El Aziz, Michael A Nauck
Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis. Journal of diabetes research 2022 (2022)
Daniel Robert Quast, Michael A Nauck, Nina Schenker, Björn A Menge, Christoph Kapitza, Juris J Meier
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes, obesity & metabolism 23 (10) (2021)
Soo Lim, Jae Hyun Bae, Hyuk-Sang Kwon, Michael A Nauck
Reply to: Autonomic dyshomeostasis in patients with diabetes mellitus during COVID-19. Nature reviews. Endocrinology 17 (3) (2021)
Jessica A Huthmacher, Juris J Meier, Michael A Nauck
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. Diabetes care 43 (9) (2021)
Matthew C Riddle, William T Cefalu, Philip H Evans, Ulagamadesan Venkatesan, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip R Schauer, Roy Taylor, Douglas Twenefour
Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 64 (11) (2021)
Matthew C Riddle, William T Cefalu, Philip H Evans, Ulagamadesan Venkatesan, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip R Schauer, Roy Taylor, Douglas Twenefour
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes care (2021)
Michael A Nauck, Daniel Robert Quast, Juris J Meier
Another milestone in the evolution of GLP-1-based diabetes therapies. Nature medicine 27 (6) (2021)
Matthew C Riddle, William T Cefalu, Philip H Evans, Ulagamadesan Venkatesan, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip Schauer, Roy Taylor, Douglas Twenefour
Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association (2021)
Matthew C Riddle, William T Cefalu, Philip H Evans, Ulagamadesan Venkatesan, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip R Schauer, Roy Taylor, Douglas Twenefour
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism (2021)
Kamlesh Khunti, Melanie J Davies, Mikhail N Kosiborod, Michael A Nauck
Long COVID - metabolic risk factors and novel therapeutic management. Nature reviews. Endocrinology 17 (7) (2021)
Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, obesity & metabolism (2021)
Shweta Urva, Tamer Coskun, Corina Loghin, Xuewei Cui, Emily Beebe, Libbey O'Farrell, Daniel A Briere, Charles Benson, Michael A Nauck, Axel Haupt
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, obesity & metabolism 22 (10) (2020)
Subodh Verma, Stephen C Bain, Julie Broe Honoré, Johannes F E Mann, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Maria Sejersten Ripa, Bernard Zinman, John B Buse
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes, obesity & metabolism 22 (11) (2020)
John B Buse, Stephen C Bain, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Richard E Pratley, Martin Linder, Tea Monk Fries, David D Ørsted, Bernard Zinman, null null
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes care 43 (7) (2020)
Soo Lim, Jae Hyun Bae, Hyuk-Sang Kwon, Michael A Nauck
COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature reviews. Endocrinology 17 (1) (2020)
Anna M Lindmeyer, Juris J Meier, Michael A Nauck
Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. Journal of diabetes science and technology 15 (6) (2020)
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism 22 (6) (2020)
Lea Aigner, Björn Becker, Sonja Gerken, Daniel R Quast, Juris J Meier, Michael A Nauck
Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. Diabetes care 44 (2) (2020)
Michael A Nauck, Melanie Kahle-Stephan, Anna M Lindmeyer, Sina Wenzel, Juris J Meier
Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy. Journal of diabetes science and technology 15 (6) (2020)
Angelica Cristello Sarteau, Milan S Geybels, Klara R Klein, Frederik F Kreiner, Nikolaus Marx, Michael A Nauck, Richard E Pratley, Benjamin O Wolthers, John B Buse
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. Diabetes, obesity & metabolism 22 (9) (2020)
Michael A Nauck, Eskil Kreiner, Søren Rasmussen, Hans A Saevereid, John B Buse, null null
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes care 43 (2) (2020)
Anne Jitschin, Sibylle Schleser-Mohr, Almut Stierling, Juris J Meier, Michael A Nauck
Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire. Acta diabetologica 57 (8) (2020)
Michael A Nauck, Michael A Nauck
Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. Diabetes care 43 (12) (2020)
Subodh Verma, Stephen C Bain, Tea Monk Fries, C David Mazer, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Hans A Saevereid, Bernard Zinman, John B Buse
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, obesity & metabolism 21 (7) (2019)
Mirna Abd El Aziz, Oscar Cahyadi, Juris J Meier, Wolfgang E Schmidt, Michael A Nauck
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, obesity & metabolism 22 (4) (2019)
Juris J Meier, Björn A Menge, Nina Schenker, Silke Erdmann, Melanie Kahle-Stephan, Freimut Schliess, Christoph Kapitza, Michael A Nauck
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Michael A Nauck, Anna M Lindmeyer, Chantal Mathieu, Juris J Meier
Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). Journal of diabetes science and technology 15 (2) (2019)
Michael A Nauck, Juris J Meier
GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. Diabetes 68 (5) (2019)
Cornelis Cees J Tack, Stephan Jacob, Cyrus Desouza, Stephen C Bain, John B Buse, Michael A Nauck, John R Petrie, Neil R Poulter, Richard E Pratley, Helen Vanya B K Stegmann, Heidrun Bosch-Traberg, Elena Startseva, Bernard Zinman, null null
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes, obesity & metabolism 21 (11) (2019)
Michael A Nauck, Darren K McGuire, Karen S Pieper, Yuliya Lokhnygina, Timo E Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D Peterson, Harvey D White, Russell Scott, Rury R Holman
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovascular diabetology 18 (1) (2019)
Michael A Nauck, Marie Louise Muus Ghorbani, Eskil Kreiner, Hans A Saevereid, John B Buse, null null
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes care 42 (10) (2019)
Michael A Nauck, John B Buse, Johannes F E Mann, Stuart Pocock, Heidrun Bosch-Traberg, Helle Frimer-Larsen, Qing Ye, Alastair Gray, null null
Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes, obesity & metabolism 21 (3) (2018)
Michael A Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna, John B Buse, null null
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes care 41 (8) (2018)
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong Yeol Park, Ye Jee Kim, Chang Hee Jung, Michael A Nauck
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. Diabetes & metabolism journal 43 (4) (2018)
Daniel Robert Quast, Michael A Nauck, F G Bechara, Juris J Meier
A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. Diabetic medicine : a journal of the British Diabetic Association 34 (8) (2018)
Michael A Nauck, Juris J Meier
Incretin hormones: Their role in health and disease. Diabetes, obesity & metabolism (2018)
Stephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen M Dungan, Maria C Faingold, Michael E Farkouh, Denise R Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F Merino-Torres, Michael A Nauck, Sue D Pedersen, Wayne H-H Sheu, Robert J Silver, Cees J Tack, Nikhil Tandon, Ole K Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, obesity & metabolism 21 (3) (2018)
Maike Haase, Melanie Kahle, Martin Janert, Juris J Meier, Michael A Nauck
Basal rate tests (24-hour fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial. Diabetes, obesity & metabolism 19 (6) (2017)
Michael A Nauck, Juris J Meier, Wolfgang E Schmidt
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials. Diabetes, obesity & metabolism 19 (9) (2017)

Michael A Nauck.css-eqlu8i{font-size:small;padding-left:4px;} (Michael Nauck, Juris J Meier, M A Nauck)

Publication Activity (10 Years)

Top Topics

Top Venues

Michael A Nauck (Michael Nauck, Juris J Meier, M A Nauck)